August 5, 2015

Congratulations to Dr. Frits van Rhee on his newest publication

Congratulations to the international expert, our own Dr. Frits van Rhee, on his newest publication, “A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease”.

Be sure to check it out!
Read here on Onctotarget